辛伐他汀治疗急性冠脉综合征120例

Efficacy of simvastatin on acute coronary syndrome in 120 cases

目的观察辛伐他汀对急性冠脉综合征的临床疗效。方法选择120例急性冠脉综合征患者,治疗组60例在常规治疗的基础上给予辛伐他汀20mg口服,每晚1次;对照组只给予基础药物治疗,疗程均为2个月。2个月后观察两组血脂情况及再住院率。结果2个月后治疗组患者甘油三酯、胆固醇、低密度脂蛋白及高敏C反应蛋白明显降低,高密度脂蛋白升高,与治疗前比较差异有统计学意义(P<0.05);对照组治疗前后血脂比较差异无统计学意义(P>0.05);因心肌缺血症状需再次住院的例数,治疗组与对照组比较差异有统计学意义(P<0.05)。结论辛伐他汀可调脂和减少急性冠脉综合征再住院率。

Objective To investigate the clinical efficacy of simvastatin on acute coronary syndrome （ACS）. Methods Altogether 120 patients with ACS were randomly divided into treatment group （ n = 60） and control group （ n = 60）. Patients in treatment group received 20 mg simvastatin per night on the basis of conventional treatment. And patients in control group received conventional treatment only. Two months later the serum lipid levels and re-admission incidence were observed. Results In treatment group,the levels of triglyceride,cholesterol,lowdensity lipoprotein and high sensitive-C reactive protein decreased markedly and highdensity lipoprotein increased significantly compared with which before treatment （ P〈0.05）. There was no statistical difference on the levels of serum lipid post treatment in patients of conventional treatment. There was statistical difference on re-admission incidence for myocardial ischemia between treatment group and control group （ P〈0.05）. Conclusion Simvastatin is capable of regulating lipid and decreasing re-admission incidence in acute coronary syndrome.